Skip to main content
Clinical Trials/NCT01511458
NCT01511458
Completed
Not Applicable

Non-invasive Chromosomal Examination of Trisomy

Roche Sequencing Solutions36 sites in 6 countries18,955 target enrollmentMarch 2012
ConditionsTrisomy 21

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Trisomy 21
Sponsor
Roche Sequencing Solutions
Enrollment
18955
Locations
36
Primary Endpoint
Difference in sensitivity and specificity of Ariosa Harmony™ Prenatal Test (AUCt) and combined first-trimester screening for detection of T21.
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this blinded, multi-center, prospective, case-controlled study is to compare the Ariosa Harmony™ Prenatal Test for trisomy 21 detection with a standard first-trimester prenatal screening test consisting of serum screening (PAPP-A,free beta-hCG [β-hCG] or total hCG) and a nuchal translucency (NT) measurement (i.e. combined first trimester screening) in a general screened population.

The performance characteristics of these two test modalities will be assessed relative to the clinical reference standard of genetic analysis of the fetus or phenotypic characterization and genetic analysis of the newborn.

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
May 2014
Last Updated
11 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Roche Sequencing Solutions
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject is at least 18 years old and can provide informed consent.
  • Subject is planning a hospital delivery.
  • Subject has a singleton pregnancy with a documented gestational age between 10 weeks, 0 days, and 14 weeks, 2 days, inclusive, at the time of the study blood sample collection.
  • Subject is planning to undergo combined first trimester prenatal screening that includes NT measurement, and when indicated, serum screening with total or free β-hCG and PAPP-A.

Exclusion Criteria

  • Subject has known aneuploidy.
  • Subject has active or history of malignancy requiring major surgery and/or systemic chemotherapy.
  • Subject has a twin demise at any gestational age. Twin demise includes any reductions, spontaneous or elective, after sonographic identification of a second (or more) gestational sac. Any clinical, sonographic, or other testing that suggests twin demise would serve as an exclusion criterion.

Outcomes

Primary Outcomes

Difference in sensitivity and specificity of Ariosa Harmony™ Prenatal Test (AUCt) and combined first-trimester screening for detection of T21.

Time Frame: Enrollment to delivery

Study Sites (36)

Loading locations...

Similar Trials